Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 36 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka Therapeutics to related companies based on the strength of its dividends, profitability, risk, institutional ownership, valuation, analyst recommendations and earnings.
Profitability
This table compares Oruka Therapeutics and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Oruka Therapeutics | N/A | -20.18% | -19.51% |
Oruka Therapeutics Competitors | -456.55% | -21.40% | -14.61% |
Valuation and Earnings
This table compares Oruka Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Oruka Therapeutics | N/A | -$5.34 million | -4.96 |
Oruka Therapeutics Competitors | $602.66 million | $7.11 million | -35.52 |
Institutional and Insider Ownership
56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 47.3% of shares of all “Diagnostic substances” companies are owned by institutional investors. 30.9% of Oruka Therapeutics shares are owned by insiders. Comparatively, 12.7% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for Oruka Therapeutics and its peers, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Oruka Therapeutics | 0 | 0 | 6 | 2 | 3.25 |
Oruka Therapeutics Competitors | 852 | 800 | 1339 | 23 | 2.18 |
Oruka Therapeutics currently has a consensus price target of $43.17, suggesting a potential upside of 45.05%. As a group, “Diagnostic substances” companies have a potential upside of 33.53%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Oruka Therapeutics is more favorable than its peers.
Volatility and Risk
Oruka Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ peers have a beta of 1.20, indicating that their average stock price is 20% more volatile than the S&P 500.
Summary
Oruka Therapeutics beats its peers on 9 of the 13 factors compared.
Oruka Therapeutics Company Profile
ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.